Quick Answer
IMMUNIC, INC. reported Cash and Equivalents of $15.48 million for fiscal year 2025.
IMMUNIC, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.48M | -56.6% |
| 2024 | $35.67M | -23.6% |
| 2023 | $46.67M | -56.3% |
| 2022 | $106.75M | +22.9% |
| 2021 | $86.86M | -31.8% |
| 2020 | $127.45M | +334.0% |
| 2019 | $29.37M | +124.7% |
| 2018 | $13.07M | -77.0% |
| 2017 | $56.90M | -5.2% |
| 2016 | $59.99M | -28.1% |
| 2015 | $83.42M | -18.4% |
| 2014 | $102.24M | +167.7% |
| 2013 | $38.19M | +752.9% |
| 2012 | $4.48M | +457.5% |
| 2011 | $803.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.13M | -40.5% | -36.5% |
| June 30, 2025 | $55.31M | -30.6% | +286.7% |
| March 31, 2025 | $14.30M | -85.3% | -59.9% |
| December 31, 2024 | $35.67M | -23.6% | -39.6% |
| September 30, 2024 | $59.07M | -1.0% | -25.9% |
| June 30, 2024 | $79.70M | +3.1% | -18.1% |
| March 31, 2024 | $97.31M | +4.9% | +108.5% |
| December 31, 2023 | $46.67M | -56.3% | -21.8% |
- IMMUNIC, INC. showed a decrease of -56.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, IMMUNIC, INC.’s cash and equivalents has grown by 1828.1% (from $803.0 thousand to $15.48 million).
- The most recent figure is from IMMUNIC, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: